...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality
【24h】

Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality

机译：Empagliflozin与Liraglutide预防心血管死亡率的有用性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Empagliflozin, an inhibitor of sodium–glucose cotransporter 2 and Liraglutide, a glucagon-like peptide 1 analogue, were both proved to significantly reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes and established CV disease. However, addition of either drug to current diabetes treatment regimens may impose a significant burden on healthcare systems. We performed a cost-minimization analysis of Empagliflozin versus Liraglutide for preventing CV death. Rates of prevention of CV death were extracted from the published data of the EMPA-REG OUTCOME and LEADER trials. Drug costs were extracted from the US National Average Drug Acquisition Costs of 2017. In the EMPA-REG OUTCOME trial 5,833 patient-years of treatment with Empagliflozin resulted in the prevention of 51 CV deaths. In LEADER, 16,338 patient-years of Liraglutide resulted in the prevention of 59 CV deaths. The price in 2017 of annual Empagliflozin and Liraglutide therapy was $4,980 and $9,300, respectively. Therefore, the cost of Empagliflozin or Liraglutide needed to prevent 1 CV death would be $569,526 (95% confidence interval $415,713 to $921,798) and $2,575,312 (95% confidence interval $1,607,526 to $7,807,986), respectively. In conclusion, use of Empagliflozin for preventing CV death in type 2 diabetes patients with an established CV disease seems to be a major cost-saving strategy compared with Liraglutide. These results should be considered in the context of other individual drug and patient factors.
机译：Empagliflozin，钠葡萄糖分类剂2和丽格肽的抑制剂，胰高血糖素样肽1类似物，被证明是显着降低2型糖尿病患者心血管（CV）死亡的发生率，并建立了CV疾病。然而，向当前糖尿病治疗方案添加任何药物可能对医疗保健系统产生重大负担。我们对Empagliflozin对Liraglutide进行了成本最小化分析，用于防止CV死亡。从EMPA-REG结果和领导者试验的公布数据中提取了预防CV死亡率。从美国国家平均药物收购成本中提取了药物成本2017年。在Empa-Reg成果试验中，患有Empagliflozin的患者 - 多年治疗导致预防51只CV死亡。在领导者中，16,338名患者患者的黎拉格勒蛋白质导致预防59只CV死亡。 2017年年度Empagliflozin和Liraglutide治疗的价格分别为4,980美元和9,300美元。因此，预防1个CV死亡所需的Empagliflozin或Liraglutide的成本将分别为569,526美元（95％的置信区间415,713美元至921,798美元），分别为2,575,312美元（95％的信心间隔1,607,526美元至7,807,986美元）。总之，与Liraglutide相比，使用Empagliflozin用于预防2型糖尿病患者的糖尿病患者的CV患者似乎是一种重大的节省成本策略。在其他个体药物和患者因素的背景下应考虑这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号